OptiNose Inc (NASDAQ:OPTN) saw a significant increase in short interest in November. As of November 15th, there was short interest totalling 841,944 shares, an increase of 63.0% from the October 31st total of 516,381 shares. Based on an average daily volume of 166,017 shares, the days-to-cover ratio is presently 5.1 days. Approximately 7.2% of the company’s shares are short sold.

Several research analysts recently issued reports on the company. Piper Jaffray Companies assumed coverage on OptiNose in a research note on Tuesday, November 7th. They issued an “overweight” rating and a $27.00 price objective on the stock. Jefferies Group assumed coverage on OptiNose in a research note on Tuesday, November 7th. They issued a “buy” rating and a $27.00 price objective on the stock. BMO Capital Markets assumed coverage on OptiNose in a research note on Tuesday, November 7th. They issued an “outperform” rating and a $29.00 price objective on the stock. Finally, Royal Bank Of Canada assumed coverage on OptiNose in a research note on Tuesday, November 7th. They issued an “outperform” rating and a $33.00 price objective on the stock.

OptiNose (NASDAQ OPTN) opened at $18.53 on Monday. OptiNose has a 52 week low of $15.01 and a 52 week high of $21.46.

ILLEGAL ACTIVITY NOTICE: “Short Interest in OptiNose Inc (OPTN) Increases By 63.0%” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/short-interest-in-optinose-inc-optn-increases-by-63-0/1742441.html.

OptiNose Company Profile

OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.

Receive News & Ratings for OptiNose Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.